The main objective of this study is to determine the mass balance, routes of elimination, and pharmacokinetics of \[14C\]-BGB-11417 in healthy male participants along with determining the concentrations of radioactivity in plasma, fecal and urinary elimination of total radioactivity.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Area under the concentration curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of BGB-11417
Timeframe: From 0 to 168 hours after study drug administration
Maximum concentration (Cmax) of BGB-11417 in Plasma
Timeframe: From 0 to 168 hours after study drug administration
Time to Cmax (Tmax) of BGB-11417 in Plasma
Timeframe: From 0 to 168 hours after study drug administration
Amount of BGB-11417-106 excreted (Ae) and Cumulative amount of BGB-11417-106 (Cum Ae) excreted in urine and feces
Timeframe: From 0 to 168 hours after study drug administration
Percentage (%Fe) and cumulative percentage (Cum %Fe) of BGB-11417 or radioactive dose excreted in urine and feces
Timeframe: From 0 to 168 hours after study drug administration